Synthesis and antitumor activity evaluations of albumin-binding prodrugs of CC-1065 analog

Bioorganic & Medicinal Chemistry
2008.0

Abstract

An albumin-binding prodrug of the extremely potent CC-1065 analog, (+)-FDI-CBI, has been synthesized. This analog, (+)-FDI-CBIM, formed an albumin conjugate when added to human albumin in vitro. A greater amount (>3-fold) of the prodrug can be administered to animals compared to the free drug. The prodrug had significantly improved antitumor efficacy compared to the free drug in animal models using syngeneic animal tumors and human ovarian xenografted tumor cells. Antitumor drug delivery by in situ formation of drug-albumin conjugate is a promising strategy to improve antitumor efficacy.

Knowledge Graph

Similar Paper

Synthesis and antitumor activity evaluations of albumin-binding prodrugs of CC-1065 analog
Bioorganic & Medicinal Chemistry 2008.0
Synthesis and Antitumor Efficacy of a β-Glucuronidase-Responsive Albumin-Binding Prodrug of Doxorubicin
Journal of Medicinal Chemistry 2012.0
Probing the Cysteine-34 Position of Endogenous Serum Albumin with Thiol-Binding Doxorubicin Derivatives. Improved Efficacy of an Acid-Sensitive Doxorubicin Derivative with Specific Albumin-Binding Properties Compared to That of the Parent Compound
Journal of Medicinal Chemistry 2002.0
Design, Synthesis, and Evaluation of Duocarmycin O-Amino Phenol Prodrugs Subject to Tunable Reductive Activation
Journal of Medicinal Chemistry 2010.0
CC-1065 Analogues Bearing Different DNA-Binding Subunits:  Synthesis, Antitumor Activity, and Preliminary Toxicity Study
Journal of Medicinal Chemistry 2003.0
Synthesis and biological characterization of ubenimex-fluorouracil conjugates for anti-cancer therapy
European Journal of Medicinal Chemistry 2018.0
Novel Cyclopropylindole Conjugates and Dimers: Synthesis and Anti-Cancer Evaluation
Current Medicinal Chemistry-Anti-Cancer Agents 2001.0
A β-glucuronidase-responsive albumin-binding prodrug for potential selective kinase inhibitor-based cancer chemotherapy
European Journal of Medicinal Chemistry 2018.0
A Bioreductive Prodrug of Cucurbitacin B Significantly Inhibits Tumor Growth in the 4T1 Xenograft Mice Model
ACS Medicinal Chemistry Letters 2019.0
Synthesis and Preliminary Biological Evaluations of CC-1065 Analogues:  Effects of Different Linkers and Terminal Amides on Biological Activity
Journal of Medicinal Chemistry 2000.0